Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
52-week High/Low: $5.00 / $0.70
Sector: Health Care, Equipment & Services
Market Cap: $5.54M
Pressure BioSciences Inc (OTCMKTS:PBIO)

Pressure BioSciences Inc

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform...

Pressure BioSciences Inc

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Pressure BioSciences Inc

Pressure BioSciences Inc Snapshot

We are a life sciences company focused on the development and commercialization of a novel, enabling, platform technology called pressure cycling technology ("PCT"). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions.

Our pressure cycling technology uses internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures to rapidly and repeatedly control the interactions of bio-molecules. Our instrument, the Barocycler®, and our internally developed consumables product line, which includes PULSE (Pressure Used to Lyse Samples for Extraction) Tubes as well as the ProteoSolveLRS™ kit for the detergent-free extraction of proteins from lipid-rich samples, together make up the PCT Sample Preparation System ("PCT SPS").

Our pressure cycling technology employs a unique approach that we believe has the potential for broad applications in a number of established and emerging life sciences areas, including;

Sample preparation for genomic, proteomic, and small molecule studies;

Pathogen inactivation;

Protein purification;

Control of chemical (enzymatic) reactions; and


Since we began operations as Pressure BioSciences in February 2005, we have focused substantially all of our research and development and commercialization efforts on sample preparation for genomic, proteomic, and small molecule studies.

Our business strategy is to commercialize pressure cycling technology in the area of sample preparation for genomic, proteomic, and small molecule studies ("sample preparation"). We also plan to pursue the further development and commercialization of PCT in other life sciences applications, which could include working with various strategic partners that have greater scientific, and regulatory, expertise in the respective applications than we do.

Pressure Cycling Technology (PCT)

Pressure BioSciences, Inc. (OTCQB: PBIO) is a life sciences tools company focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on our game-changing Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (up to 90,000 psi) to safely, conveniently and reproducibly control the actions of molecules in biological samples, e.g., the rupture (lysis) of cells and tissues from human, animal, plant, and microbial sources, and the inactivation of pathogens.

We currently focus the majority of our efforts on the development and sale of PCT-enhanced systems (instruments and consumables) to address the challenging problems inherent in biological sample preparation, a crucial laboratory step performed by tens of thousands of scientists worldwide working in biological life sciences research. Through 2015, we have nearly 300 PCT Systems installed in over 150 leading academic, government, biotech, and pharma laboratories worldwide, with primary applications in biomarker discovery, forensics, agriculture, and pathology. There are over 100 scientific papers published on the advantages of the PCT platform, many by key opinion leaders worldwide. Such advantages include: (a) extraction and recovery of more membrane proteins, (b) enhanced protein digestion, (c) differential lysis in a mixed sample base, (d) pathogen inactivation, (e) increased DNA detection, and (f) exquisite sample preparation process control.

On January 12, 2016, SCIEX, a global leader in life science analytical technologies, announced an exclusive co-marketing agreement with PBI. This relationship will uniquely position SCIEX to address a major challenge in complex sample preparation by marketing a complete solution to increase the depth, breadth, and reproducibility of protein extraction, digestion and quantitation in all tissue types, including challenging samples like tumors. This focus on improved sample preparation will enable scientists to extract more proteins reproducibly from complex sample types, potentially yielding superior biological insights and discoveries.


For more information on the different products, please click the pictures below:



Jeffrey Peterson







Mr. Jeffrey N. Peterson is the Chairman of the Board of Directors. He is also the CEO of Target Discovery, Inc. (Palo Alto, CA), a Personalized Medicine Diagnostics company leveraging proprietary proteomics tools, to identify and leverage the "missing link" in biochemical pathway control and biomarker utility: the specific modification states of proteins (isoforms). Mr. Peterson serves as Chairman of TDI's majority-owned subsidiary company Veritomyx, Inc., developing breakthrough tools in accurate peptide, protein, isoform and metabolite identification and characterization.
Mr. Peterson brings broad executive general management, multi-functional, multi-business and international experience to these roles. Prior to Target Discovery, he served as CEO of Sharpe, Peterson, Ocheltree & Associates, an international business development consulting firm assisting Fortune 500 and many smaller firms in business expansion and strategy. He spent 9 years in key management roles in Abbott Laboratories’ Diagnostics and International (Pharmaceuticals, Hospital Products, Nutritionals, Consumer) businesses, last serving as CEO and General Manager of Abbott South Africa, where he doubled the sales and tripled the income of this 50 year-old business in 3.5 years, during the tumult of South Africa’s political transition. He played an earlier pivotal management role in Abbott’s successful introduction and support of multiple new diagnostics instrument and reagent systems in the history-making X-System series, including the IMx (the highest global sales diagnostic system in history).
Mr. Peterson's experience prior to Abbott included 11 years with General Electric’s Engineered Materials and Plastics businesses, spanning roles in strategic planning, business development, technology licensing, marketing/sales, operations/quality and R&D. He holds BSChE and MSChE (Chemical Engineering) degrees from MIT. Mr. Peterson is Chair Emeritus of the BayBio Institute, a non-profit organization serving the regional life science community, and serves on the Board of BayBio, the trade association for the life sciences industry in Northern California. He is a co-founder of the Coalition for 21st Century Medicine, and of BIO's Personalized Medicine & Diagnostics Group.     


mickey urdea







Dr. Urdea has devoted his 30-year career to human diagnostics in a variety of capacities. He has been involved in the discovery of new biomarkers, the development of new technologies for biomarker discovery, validation and commercialization, diagnostic test development, manufacturing and marketing, and the management of companies involved in these activities. Dr. Urdea founded and is a Managing Partner for Halteres Associates, a biotechnology consulting firm. He also founded and served as Chief Executive Officer of Tethys Bioscience, a proteomics-based diagnostics company involved in preventative personalized medicine. Tethys’ first product was the protein-based PreDx Diabetes Risk Score Test, which was introduced in 2008. Additionally, Dr. Urdea is a founder and the Chairman of Catalysis Foundation for Health, an organization addressing gaps in global healthcare caused by inefficiencies in disease diagnosis and monitoring. He serves as an expert consultant to the life sciences industry and is on the scientific advisory boards and boards of directors of a number of biotechnology, diagnostics, venture capital and philanthropic organizations.

Prior to his current business activities, Dr. Urdea founded the Nucleic Acid Diagnostics group at Chiron Corporation, and with colleagues, invented branched DNA molecules for amplification of signal in nucleic acid complexes. Application of this technology resulted in the first commercial products for quantification of human hepatitis B, hepatitis C, and human immunodeficiency viruses (HBV, HCV, and HIV, respectively). He then became business head of the Molecular Diagnostics group and Chief Scientific Officer at Bayer Diagnostics. He was also a member of the Bill and Melinda Gates Foundation Diagnostic Forum. Dr. Urdea is an author on nearly 200 peer-reviewed scientific publications, nearly 300 abstracts and international scientific presentations, and more than 100 issued and pending patents. He received his BS in Biology and Chemistry from Northern Arizona University in Flagstaff and his Ph.D in Biochemistry from Washington State University in Pullman.

V Mangiardi







Mr. Vito Mangiardi Energy product and service sectors. He is a strong P&L performer and corporate strategist in General Management, Operations, Sales/Marketing, and Science. Mr. Mangiardi has held positions as a Research Chemist for Bio-Rad Laboratories; Sales & Marketing Director for Baxter Travenol, Inc.; Executive VP and COO for Quintiles Transnational; President and CEO of Diagnostics Laboratories, Inc., Clingenix, Inc., and Bilcare, Inc.; and President of AAI Pharma, Inc. More recently he was the COO/Deputy Director of Operations and Production at the University of California Lawrence Berkeley National Laboratory Joint Genome Institute. Mr. Mangiardi has experience with three start-ups, two midsize, and several mature companies, and has international experience leading and managing organizations on four continents. He has vast experience in leading alliances, acquisitions, due diligence, and post-acquisition assimilation.

Mr. Mangiardi has been on the Board of Directors of three companies and has proven success in working with both national and international investment groups to raise funds. Mr. Mangiardi earned a BS in Biology/Chemistry from Eastern Illinois University and two MBA degrees from Golden Gate University - in General Management and in Marketing. Mr. Mangiardi is an inventor on four patents and is a member of numerous professional organizations.


Kevin Pollack







Mr. Kevin Pollack, Esq., M.B.A., Director. Mr. Pollack is Chief Financial Officer of Opiant Pharmaceuticals, Inc. (OPNT-OTCQB), a speciality pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders. He has been an investment banker and securities attorney at Banc of America Securities LLC and Sidley Austin LLP (formerly Brown & Wood LLP), respectively, and has previous asset management experience at Paragon Capital LP. Mr. Pollack is a magna cum laude graduate of the Wharton School of the University of Pennsylvania and holds J.D. and M.B.A. degrees from Vanderbilt University, where he graduated with Beta Gamma Sigma honors. Currently, he sits on the Boards of Directors of Opiant Pharmaceuticals, Inc. and MagneGas Corporation (MNGA-NASDAQ), an alternative energy company. Mr. Pollack also is President of Short Hills Capital LLC.


richard t schumacher







Mr. Richard T. Schumacher, the founder of our Company, has served as a director of Pressure BioSciences since the formation of its legacy business, Boston Biomedica, Inc., in 1978.  He has served as CEO of Pressure BioSciences since April 2004 and President since September, 2004.  He previously served as CEO and Chairman of the Board of Boston Biomedica from 1992 to February, 2003 and as President from 1986 to August 1999. Mr. Schumacher served as the Director of Infectious Disease Services for Clinical Sciences Laboratory, a New England-based medical reference laboratory, from 1986 to 1988. From 1972 to 1985, Mr. Schumacher was employed by the Center for Blood Research, a nonprofit medical research institute associated with Harvard Medical School. Mr. Schumacher received a BS in Zoology from the University of New Hampshire.






Investor Relations Department
Pressure BioSciences, Inc.
14 Norfolk Avenue
South Easton, MA 02375
Phone (508) 230-1828      
Fax: (508) 230-1829
E-mail: [email protected]

Corporate Presentation  3rd Global Life Sciences Conference Presentation - Warsaw, Poland  10-K - Dec 31, 2014  10-Q - Sep 30, 2015
Investor Relations

Richard T. Schumacher
CEO & Founder
Pressure BioSciences, Inc.
14 Norfolk Avenue
South Easton, MA 02375
[email protected]
Phone: (508) 230-1828
Fax: (508) 230-1829

Transfer Agent

Computershare Trust Company, Inc.
350 Indiana Street, Suite 800
Golden, CO 80401
Telephone: (303) 262-0600


Marcum LLC

53 State Street
38th Floor
Boston, MA 02109

Corporate Counsel

Szaferman, Lakind, Blumstein & Blader, PC
Quakerbridge Executive Center
101 Grovers Mill Rd, Suite 200
Lawrenceville, NJ 08648

Audit Committee

Kevin Pollack, Chair; Jeffrey Peterson; Vito Mangiardi

Compensation Committee

Vito Mangiardi, Chair; Jeffrey Peterson; Kevin Pollack

Scientific Advisory Committee

Dr. Mickey Urdea

Nominations Committee

Jeffrey Peterson, Chair; Kevin Pollack; Vito Mangiardi

Pressure BioSciences Inc Timeline

Columns Including PBIO


Market Reports Including PBIO

Video RSS



© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use